Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Endocrinol Metab (Seoul). 2021 Jun;36(3):619-627. doi: 10.3803/EnM.2021.974. Epub 2021 Jun 10.
We aimed to evaluate the clinicopathological features and biological behaviors of Korean thyroid cancer patients with rare variants of papillary thyroid carcinoma (PTC) to address the ambiguity regarding the prognostic consequences of these variants.
We retrospectively reviewed the medical records of 5,496 patients who underwent thyroid surgery for PTC, between January and December 2012, in nine tertiary hospitals. Rare PTC variants included tall cell (TCV), columnar cell (CCV), diffuse sclerosing (DSV), cribriform-morular (CMV), solid (SV), hobnail, and Warthin-like variants. Recurrence-free survival (RFS) was defined as the time from the date of thyroidectomy until recurrence.
Rare variants accounted for 1.1% (n=63) of the PTC patients; with 0.9% TCV, 0.02% CCV, 0.1% DSV, 0.1% CMV, and 0.1% SV. The mean age of patients and primary tumor size were 42.1±13.1 years and 1.3±0.9 cm, respectively. Extrathyroidal extension and cervical lymph node metastasis were observed in 38 (60.3%) and 37 (58.7%) patients, respectively. Ultrasonographic findings revealed typical malignant features in most cases. During a median follow-up of 7 years, 6.3% of patients experienced a locoregional recurrence. The 5-year RFS rates were 71.4% in patients with DSV or SV, 95.9% for TCV, or CCV, and 100% for other variants. DSV emerged an independent risk factor associated with shorter RFS.
In this multicenter Korean cohort, rare variants accounted for 1.1% of all PTC cases, with TCV being the most frequent subtype. DSV emerged as a significant prognostic factor for RFS.
我们旨在评估韩国甲状腺癌患者中罕见的甲状腺乳头状癌(PTC)变体的临床病理特征和生物学行为,以解决这些变体对预后后果的模糊性。
我们回顾性分析了 2012 年 1 月至 12 月期间在 9 家三级医院接受甲状腺手术治疗 PTC 的 5496 名患者的病历。罕见的 PTC 变体包括高细胞(TCV)、柱状细胞(CCV)、弥漫性硬化(DSV)、筛状-结节状(CMV)、实性(SV)、钉突和沃辛样变体。无复发生存(RFS)定义为甲状腺切除术至复发的时间。
罕见变体占 PTC 患者的 1.1%(n=63);TCV 占 0.9%,CCV 占 0.02%,DSV 占 0.1%,CMV 占 0.1%,SV 占 0.1%。患者的平均年龄和原发肿瘤大小分别为 42.1±13.1 岁和 1.3±0.9cm。38(60.3%)例患者有甲状腺外侵犯,37(58.7%)例患者有颈部淋巴结转移。在大多数情况下,超声检查结果显示为典型恶性特征。在中位随访 7 年期间,6.3%的患者出现局部区域复发。DSV 或 SV 患者的 5 年 RFS 率为 71.4%,TCV 或 CCV 为 95.9%,其他变体为 100%。DSV 是 RFS 较短的独立危险因素。
在这个多中心的韩国队列中,罕见变体占所有 PTC 病例的 1.1%,TCV 是最常见的亚型。DSV 是 RFS 的显著预后因素。